Dr. Lau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 34th St
Fl 8
New York, NY 10016Phone+1 212-404-3696
Education & Training
University of British ColumbiaClass of 2013
Certifications & Licensure
NY State Medical License 2021 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Daratumumab in STK11 Mutated NSCLC Start of enrollment: 2023 Jun 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 33 citationsSquamous cell lung cancer: Current landscape and future therapeutic options.Sally C M Lau, Yuanwang Pan, Vamsidhar Velcheti, Kwok Kin Wong
Cancer Cell. 2022-11-14 - 22 citationsKMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.Yuanwang Pan, Han Han, Hai Hu, Hua Wang, Yueqiang Song
Cancer Cell. 2023-01-09 - 40 citationsImmunotherapy in non-small cell lung cancer: Past, present, and future directions.Salman R Punekar, Elaine Shum, Cassandra Mia Grello, Sally C Lau, Vamsidhar Velcheti
Frontiers in Oncology. 2022-01-01
Press Mentions
Tarlatamab plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung CancerOctober 8th, 2024- TKI plus Chemotherapy Prolonged Survival Outcomes in NSCLC with Brain MetastasesFebruary 22nd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
